- Home
- VSCO vs RNA Comparison
VSCO vs RNA Comparison
Compare VSCO & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSCO | RNA |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VSCO | RNA |
|---|---|---|
| Price | $60.55 | $72.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | $49.10 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 2.1M | 2.0M |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.59 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $6,390,000,000.00 | $20,868,000.00 |
| Revenue This Year | $6.58 | $57.30 |
| Revenue Next Year | $3.30 | $28.41 |
| P/E Ratio | $30.12 | ★ N/A |
| Revenue Growth | 2.95 | ★ 106.27 |
| 52 Week Low | $13.76 | $21.51 |
| 52 Week High | $66.89 | $72.61 |
Technical Indicators
Market Signals| Indicator | VSCO | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 74.81 |
| Support Level | $59.88 | $72.23 |
| Resistance Level | $65.16 | $72.47 |
| Average True Range (ATR) | 2.78 | 0.17 |
| MACD | 0.04 | -0.17 |
| Stochastic Oscillator | 56.90 | 90.18 |
Price Performance
Historical ComparisonAbout VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.